Previous 10 | Next 10 |
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stephens Annual Investme...
Glaukos Corporation (GKOS) Q3 2022 Earnings Conference Call November 02, 2022 04:30 PM ET Company Participants Chris Lewis - Vice President-Investor Relations & Corporate Affairs Tom Burns - Chairman & Chief Executive Officer Joe Gilliam - President &...
Glaukos press release ( NYSE: GKOS ): Q3 Non-GAAP EPS of -$0.45 beats by $0.07 . Revenue of $71.3M (-4.6% Y/Y) beats by $3.34M . Updated 2022 net sales guidance to $278M to $280M, compared to $275M to $280M previously. The consensus revenue estimate is $278...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2022. Key highlight...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quart...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the...
Glaukos (NYSE: GKOS) , a specialty healthcare company that concentrates on eye disorders, enjoyed a very healthy pop in its share price on Wednesday. This followed the company's latest clinical update. Investors traded the stock up by almost 19%. That update was about iDose TR, ...
Glaukos Corporation ( NYSE: GKOS ), a MedTech company focused on eye diseases, announced Wednesday that two pivotal Phase 3 trials for its eye implant iDose TR reached primary efficacy endpoints in patients with open-angle glaucoma (OAG) or ocular hypertension. iDose TR cont...
Phase 3 Pivotal Trials Met Pre-Specified Primary Efficacy Endpoints for Both Doses of iDose TR (Fast- and Slow-Release Models), Supporting Anticipated Upcoming NDA Submission 93% of Slow-Release iDose TR Subjects Remained Well-Controlled on the Same or Fewer IOP-Lowering Topic...
MIGS Corporate Pioneer Achieves Unprecedented, Market-Leading Milestone Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today annou...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...